Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University, Zhejiang University, Hangzhou, China.
Pharmacol Res. 2021 Jul;169:105684. doi: 10.1016/j.phrs.2021.105684. Epub 2021 May 19.
Osteosarcoma, a highly malignant tumor, is characterized by widespread and recurrent chromosomal and genetic abnormalities. In recent years, a number of elaborated sequencing analyses have made it possible to cluster the osteosarcoma based on the identification of candidate driver genes and develop targeted therapy. Here, we reviewed recent next-generation genome sequencing studies and advances in targeted therapies for osteosarcoma based on molecular classification. First, we stratified osteosarcomas into ten molecular subtypes based on genetic changes. And we analyzed potential targeted therapies for osteosarcoma based on the identified molecular subtypes. Finally, the development of targeted therapies for osteosarcoma investigated in clinical trials were further summarized and discussed. Therefore, we indicated the importance of molecular classification on the targeted therapy for osteosarcoma. And the stratification of patients based on the genetic characteristics of osteosarcoma will help to obtain a better therapeutic response to targeted therapies, bringing us closer to the era of personalized medicine.
骨肉瘤是一种高度恶性的肿瘤，其特征是广泛存在且反复发生的染色体和基因异常。近年来，大量详细的测序分析使我们能够根据候选驱动基因的鉴定对骨肉瘤进行聚类，并开发靶向治疗。在这里，我们综述了基于分子分类的骨肉瘤的最新下一代基因组测序研究和靶向治疗进展。首先，我们根据遗传变化将骨肉瘤分为十个分子亚型。然后，我们根据鉴定出的分子亚型分析了骨肉瘤的潜在靶向治疗方法。最后，进一步总结和讨论了临床试验中针对骨肉瘤的靶向治疗的发展。因此，我们指出了分子分类对骨肉瘤靶向治疗的重要性。基于骨肉瘤的遗传特征对患者进行分层有助于获得更好的靶向治疗反应，使我们更接近个性化医疗时代。
